Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-07-235: Continued Development and Maintenance of Software (R01) (Multiple ICs)

    • Release Date: February 23, 2007
    • Application Receipt Date: May 17, 2007 and September 13, 2007
    • Expiration Date: September 14, 2007
    • Contacts:

      Jennifer A Couch, Ph.D., NCI, Phone: 301-435-5226, Email:

    • Peer Review Date(s): October, 2007 and February, 2008

    Biomedical research laboratories increasingly undertake a software development project to solve a problem of interest to that laboratory. These software packages sometimes become useful to a much broader community of users that can include translational and clinical researchers. The goal of this program announcement is to support the continued development, maintenance, testing and evaluation of existing software. The proposed work should apply best practices and proven methods for software design, construction, and implementation to extend the applicability of existing biomedical informatics/computational biology software to a broader biomedical research community.


  • Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-07-270); (R21: PAR-07-271)

    This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

    URL: (R01) (R21)

  • Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) (NIDDK, NIBIB, NIAAA) (PA-07-258)

    • Release Date: December 21, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: Expiration Date: September 2, 2008
    • Contacts:

      Contact: John Cole, Ph.D., NCI, Phone: 301-496-1718, Email:

    Research activities are encouraged in the broad areas of etiology and etiologic mechanism(s) of liver cancer, including: Identification of viral and host factors; development of animal models and in vitro viral cultivation methods; development of prevention and control strategies, including chemoprevention, validation of markers, and clinical trials of promising agents; and conduct of treatment and diagnosis research, including imaging studies.


  • PA-07-260 & PA-06-281: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

    • Release Date: December 21, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 3, 2009
    • Contacts:

      Louise Wideroff, Ph.D., NCI, Phone: 301-435-6823, Email:

    The purpose is to invite applications for health services research addressing utilization of cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

    See full description in NIH Guide: R01 PA-07-260; R21 PA-06-281

  • Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01) (PA-07-165)

    • Release Date: December 14, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: December 31, 2009, unless reissued
    • Contacts:

      Suresh Mohla, Ph.D., NCI, Phone: 301-435-1878, Email:

    The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research on the lymphatic system, to characterize its function on the molecular, cellular, tissue, organ, and intact organism levels and pathophysiologic mechanisms that cause disease, to develop new methods for imaging and/or quantitating lymph flow, and to discover new therapeutic interventions, including nursing, complementary and alternative treatments.


  • Ancillary Studies to the AD Neuroimaging Initiative (R01) (NIA, NIBIB) (PA-07-134)

    • Release Date: December 13, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: November 6, 2007
    • Contacts:

      Suresh Mohla, Ph.D., NCI, Phone: 301-435-1878, Email:

    This FOA invites research grant applications for ancillary studies to the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multi-site, longitudinal, prospective, naturalistic study of normal cognitive aging, mild cognitive impairment (MCI), and early Alzheimer's disease (AD). The ADNI is collecting, processing, and storing serial blood, CSF, and urine samples in the three groups for analyses for potential biomarkers of disease progression, including genomic, proteomic, and metabolomic markers that can be correlated with clinical, neuropsychological, and imaging data.

  • Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/R44]) (PAR-07-160)
    Innovations in Biomedical Computational Science and Technology Initiative (STTR [R41/R42]) (PAR-07-161)

    BISTI targets support for fundamental research in biomedical computing science and technology as well as the development and application of new biocomputing tools or technologies for a particular area(s) of scientific opportunity in biomedical research.

    Programs may target one or multiple areas of biomedical computing that will enable progress in biomedical research. Examples of data types that could be considered include but are not limited to genomic sequences, biomedical images, qualitative descriptors for health and social science, remote sensing and geospatial images, and pathway data.

    URLs: (SBIR) (STTR)

  • Shared Instrumentation Grant Program (S10) (NCRR) (PAR-07-105)

    • Release Date: December 06, 2006
    • Application Receipt Date: March 21, 2007
    • Expiration Date: March 22, 2007
    • Contacts:

      Marjorie A. Tingle, Ph.D., NCRR, Phone 301-435-0772, Email:

    The NCRR Shared Instrument Grant (SIG) program solicits applications from groups of NIH-supported investigators to purchase or upgrade commercially available instruments that cost at least $100,000. The maximum award is $500,000. Types of instruments supported include confocal and electron microscopes, biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell sorters, X-ray diffraction systems, and NMR spectrometers among others.


  • NOT-FD-06-001: Notice of Availability of Funds to Support Clinical trials on the Safety and Effectiveness of Products for Rare Diseases (FDA)

    • Release Date: November 27, 2006
    • Application Receipt Date: February 7, 2007
    • Expiration Date: N/A
    • Contacts:

      Debra Y. Lewis, O.D., (; Phone: 301-827-0059

    The Food and Drug Administration's (FDA) Office of Orphan Products Development (OPD) is pleased to announce the availability of funds for fiscal year (FY) 2008 grant awards to support clinical trials on the safety and effectiveness of products for rare diseases and conditions. Contingent on availability of FY 2007 and FY 2008 funds, it is anticipated that $14.2 million will be available for new applications, competing awards, and non competing continuation awards. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products. In the FDA OPD grants program, products for rare diseases and conditions (orphan products) are defined as drugs, biologics, medical devices, and medical foods indicated to treat or diagnose a rare disease or condition with a prevalence of fewer than 200,000 people in the United States.

    See Notice in NIH Guide:NOT-FD-06-001

  • PAR-06-540: Cancer Education Grants Program (R25)

    • Release Date: August 30, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: March 2, 2008
    • Contacts:

      Lester S. Gorelic, Ph.D., Phone: 301-496-8580, Email:

    This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

    Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

    The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

    See full description in NIH Guide:PAR-06-540